Login
Existing Account

Please login first to complete purchase/ quotation request, view custom order reports, or create favorites list.

Customer ID:
Password:
Stay Logged In


Forgot your Customer ID or Password?
New Account

Don't have an account with us yet? Please set up an account to place order or obtain customer services.

Antibodies  >  OptimAb Antibodies  >>  OptimAbᵀᴹ Lymphatic Endothelial Marker , Monoclonal Antibody, purified

Product Name OptimAbᵀᴹ Lymphatic Endothelial Marker , Monoclonal Antibody, purified  NEW
Clone: D2 - 40; Host: Mouse, Monoclonal Antibody
Size 25 g
Catalog # SIG-3730-25
US$ $108
Description

M2A oncofetal antigen (also called Lymphatic Endothelial Marker) is an O-linked sialoglycoprotein (40 kDa) expressed on the cell membrane of lymphatic endothelium, fetal gonocytes and certain germ cell tumor cell lines. Clone D2-40 targets the M2A antigen, and no reactivity is observed on cancer cell lines of human breast, prostate, melanoma, cervix, colon, pharynx, brain and bone marrow. In recent studies, clone D2-40 (D240) has shown staining in lymphatic channel endothelium but not in the adjacent capillary.
This monoclonal Ab is used for the qualitative identification of Lymphatic Endothelial Marker in human biological samples using immunohistochemistry (IHC) methods. The clinical interpretation of any staining or its absence should be complemented by morphological studies and proper controls and should be evaluated within the context of the patient's clinical history and other diagnostic tests by a qualified pathologist.

Host:Mouse
Clone: D2-40
Isotype: IgG1
Reactivity: Human
Immunogen: M2A antigen
Concentration:Lot specific
Formulation:PBS + 0.1% sodium azide; The Ab was ammonium sulfate precipitated from the D2-40 hybridoma cell culture supernatant
Applications:For research use applications; this Ab is effective in immunohistochemistry (IHC).
Working Dilutions:IHC: 1/40

Detailed Information Datasheet
Storage 4C
References 1, Choi WW, et al. (2005) Mod. Pathol. 18: 143-152.
2, Chu, AY, et al. (2005) Mod. Pathol. 18: 97-104.
3, Galambos C & Nodit L. (2005) Ped. Dev. Pathol. 8(2): 181-189.
4, Fogt F, et al. (2004) Oncol. Rep. 11: 47-50.
5, Fogt F, et al. (2004) Int.J. Molec. Med. 13: 681-683.
6, Franchi A et al. (2004) Cancer 101(5): 973-978.
7, Franke FE, et al. (2004) J. Cutan. Pathol. 31: 362-367.
8, Giorgadze TA, et al. (2004) J. Cutan. Pathol. 31: 672-677.
     
  < Back